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Abstract 
Morning hypertension is an independent risk for cerebrovascular and cardiovascular 
events. Although the prevalence of morning hypertension increases with age, treatment 
of morning hypertension has not been established, particularly in very elderly patients. 
We compared the safety and efficacy of a losartan/ hydrochlorothiazide (HCTZ) 
combination in controlling morning hypertension between Very-Elderly (≥75 years) and 
Young/Elderly patients (<75 years). This study was a subanalysis of the Morning 
Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination 
Therapy study, in which patients with morning hypertension (>135/85 mmHg) received 
a 50-mg losartan/12.5-mg HCTZ combination tablet (combination therapy) or 100-mg 
losartan (high-dose therapy) for 3 months. High adherence rates and few adverse effects 
were observed in Very-Elderly patients receiving combination (n=32) and high-dose 
(n=34) therapies and in Young/Elderly patients receiving combination (n=69) and 
high-dose (n=66) therapies. Baseline morning systolic BP (SBP) was similar in both age 
groups receiving either therapy. Morning SBP was reduced by 20.2 mmHg and 18.1 
mmHg with combination therapy and by 7.1 mmHg and 9.1 mmHg with high-dose 
therapy in the Very-Elderly and Young/Elderly patients, respectively. Morning BP target 
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(<135/85 mmHg) was achieved in 40.6% and 55.1% by combination therapy and in 
14.7% and 24.2% by high-dose therapy in the Very-Elderly and Young/Elderly patients, 
respectively. Neither therapy changed renal function and serum potassium in 
Very-Elderly patients. In conclusion, the losartan/HCTZ combination was safe and 
effective in controlling morning hypertension in Very-Elderly as well as Young/Elderly 
patients. In addition, combination therapy was also superior to high-dose therapy for 
lowering morning SBP in Very-Elderly patients. 
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Introduction 
Morning hypertension, which is defined as the elevation of blood pressure (BP) in the 
early morning based on BP self-measurements performed at home, is an independent 
risk factor for cerebrovascular and cardiovascular events (1). As the incidence of 
morning hypertension increases with age (2), its management is becoming increasingly 
important in our current aging society. However, morning hypertension treatment has 
not been established, especially in very elderly patients. 
Combinations of two or more antihypertensive agents are required in the 
majority of hypertensive patients (3). As it has been shown that the combination of an 
angiotensin receptor blocker (ARB) and a small dose of hydrochlorothiazide (HCTZ) 
have complementary mechanisms of action, effectively reduce BP, and are generally 
well tolerated, these drugs are often administered together (4,5). Our previous 
multicenter, prospective, randomized clinical trial Morning Hypertension and 
Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) 
study demonstrated that a 3-month treatment of losartan/ HCTZ combination therapy 
was superior to high-dose losartan therapy in reducing morning systolic BP (SBP) (6). 
However, it remains unknown whether a losartan/HCTZ combination would be safe and 
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effective for morning hypertension treatments in very elderly patients. Therefore, this 
study investigated the safety and efficacy of losartan/HCTZ combination therapy in 
patients with morning hypertension (>135/85 mmHg) aged <75 years (Young/Elderly 
group) and those aged ≥75 years (Very-Elderly group), who were registered in the 
MAPPY study. 
 
Patients and methods 
Study population 
The MAPPY study was a 3-month prospective, randomized, open-labeled, 
parallel-group, multicenter trial, with a blinded end-point assessment (Clinical Trials 
Registration-Unique Identifier: NCT00795847). A total of 201 patients were enrolled in 
this subanalysis of the MAPPY study. Patients who were >75 years were allocated to 
the Very-Elderly group (n=66), while patients who were <75 years were allocated to the 
Young/Elderly group (n=135). This study was performed in accordance with the 
Declaration of Helsinki and was approved by the institutional review boards or the 
ethics committees of all of the participating institutions. All of the patients provided 
written informed consent.  
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Data collection and measurements 
The design, trial management, and primary results of the MAPPY study have been 
described elsewhere (6). Briefly, this previous study enrolled on-treatment outpatients 
who had morning hypertension. Morning hypertension was defined as a morning SBP 
≥135 mmHg, diastolic BP (DBP) ≥85 mmHg or both (7) on 7 consecutive days of the 
home BP self-measurements during the run-in period (at least 1 month). Patients were 
excluded from the study if they had secondary hypertension, malignant hypertension or 
uncontrolled hypertension, uncontrolled diabetes mellitus with an HbA1c ≥9.0%, a 
history of gout or serum uric acid ≥8.0 mg•dL-1, serum creatinine ≥2.0 mg•dL-1, serum 
potassium (K) ≥5.5 mmol•L-1, liver damage (for example, alanine aminotransferase or 
γ-GTP level >3× the upper normal limit), administration of a thiazide diuretic, 
administration of an ARB or angiotensin-converting enzyme inhibitor (ACEI) 
exceeding the standard doses approved in Japan, and the presence of contraindications 
for thiazides or ARBs. After randomization, an antihypertensive agent was switched to a 
50 mg losartan/12.5 mg HCTZ fixed-dose combination tablet (combination therapy) or 
to 100 mg losartan (high-dose therapy) once every morning without any washout period. 
If patients were receiving either an ARB or ACEI, it was changed to the appropriate test 
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drug. Once the 3-month treatment was started, there were no further changes in the 
antihypertensive agents prescribed. Patients were instructed to perform home BP 
self-measurement every day in the early morning (within 1 h after waking up, after 
urination, before dosing in the morning, before breakfast and after resting for 1-2 min in 
a sitting position) and in the evening (before bedtime, after resting for 1 to 2 min in a 
sitting position), in accordance with the Japanese Society of Hypertension Guidelines 
for the Management of Hypertension 2009 (8). Cuff oscillometry was applied through 
the use of electronic upper arm cuff devices. Each patient used the same type of home 
BP monitoring device throughout the study. On the day of the randomization, the initial 
evaluation (i.e., medical history, medications) and laboratory tests were performed after 
obtaining written informed consent. After the 3-month treatment, the follow-up 
evaluation and laboratory tests were repeated (6). The adherence rate to the medication 
was qualitatively assessed by asking the patient if he/she took the test drugs for >85%, 
50-84%, or <50% of the time during each of the 28-day visit intervals (6). 
Statistical analysis 
Statistical analysis was performed using commercially available software (IBM SPSS 
Statistics 21.0J, IBM Japan). Data are expressed as the mean±SD. Because of the 
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skewed distributions, a geometric mean (95% confidence interval) was expressed and a 
natural logarithmic transformation was performed for the triglycerides and the B-type 
natriuretic peptide (BNP). Natural logarithm-transformed values were used for the 
statistical analyses and then reconverted to antilogarithm forms. Analysis of variance 
(ANOVA) followed by a post-hoc Scheffe’s test for continuous variables or the 
chi-square test for categorized data was used for comparisons of baseline demographics 
and characteristics among the 4 groups. A chi-square test was used to compare the ratios 
of adverse events, medication adherence, and the target BP achievement among the 
groups. Repeated-measures two-way ANOVA followed by post-hoc Scheffe’s tests were 
performed to compare the morning SBP, estimated glomerular filtration rate (eGFR), 
and serum K levels between the baseline and post-treatment. Changes in the morning 
SBP were compared using two-way ANOVA followed by post-hoc Scheffe’s tests 
among the 4 groups. A p<0.05 was considered as statistically significant. 
 
Results 
Baseline characteristics and demographics 
Table 1 shows the baseline characteristics and demographics for the 66 Very-Elderly 
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and 135 Young/Elderly patients. In the Very-Elderly group, 32 subjects were 
administered the losartan/HCTZ combination therapy and 34 were given high-dose 
losartan therapy. In the Young/Elderly group, 69 subjects were administered the 
combination therapy and 66 received the high-dose therapy. The baseline morning, 
evening, and office SBP did not differ among the 4 groups. Although the Very-Elderly 
patients had a lower baseline morning, evening, and office DBP compared to the 
Young/Elderly patients, there were no differences found between the 2 treatment groups. 
Baseline eGFR and triglycerides were lower and BNP was higher in the Very-Elderly 
patients compared to the Young/Elderly patients, whereas the levels did not differ 
between the losartan/HCTZ combination and the high-dose therapies. There were no 
differences in the other baseline parameters, comorbidity, and the number of 
administered antihypertensive agents among the 4 groups. In each group, more than 
90% of the patients received either an ARB or an ACEI. 
Safety assessment 
During the 3-month treatment, most individuals in the two treatment groups of the 
Very-Elderly or Young/Elderly patients exhibited a medication adherence rate of 85% or 
more (Table 2). There were 5 (7.8%) Very-Elderly and 4 (3.0%) Young/Elderly patients 
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who experienced adverse events. There was no significant difference in the incidence of 
adverse events. Moreover, the incidence did not differ between the losartan/HCTZ 
combination and the losartan high-dose therapies in the Very-Elderly as well as in the 
Young/Elderly patients. There were no documented serious adverse effects, such as 
severe hyperkalemia, marked serum creatinine elevation, and symptomatic hypotension, 
in either of the patient groups. 
Effects on morning SBP 
The intention-to-treat analysis was performed to determine the effects of the 
losartan/HCTZ combination and the high-dose losartan therapies on the morning SBP 
levels. After the 3-month treatment, the combination therapy reduced the morning SBP 
from 154.0±11.5 to 133.8±14.9 mmHg (p<0.01), while the high-dose losartan therapy 
decreased the morning SBP from 152.6±10.0 to 145.5±16.2 mmHg (p<0.01) in the 
Very-Elderly patients (Figure 1). In the Young/Elderly patients, the combination therapy 
reduced the morning SBP from 148.8±9.3 to 130.6±9.8 mmHg (p<0.01), while the 
high-dose therapy reduced the morning SBP from 150.1±8.7 to 141.1±12.3 mmHg 
(p<0.01). The combination therapy decreased the post-treatment morning SBP to levels 
that were lower than the high-dose therapy in the Very-Elderly and Young/Elderly 
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patients (p<0.05 and p<0.01, respectively). 
 In the Very-Elderly patients, the target achievement rates for the morning BP 
after the 3-month treatment were 40.6% for the losartan/HCTZ combination therapy and 
14.7% for the high-dose losartan therapy. In the Young/Elderly patients, the 
achievement rates were 55.1% for the combination therapy and 24.2% for the high-dose 
therapy. The combination therapy exhibited higher target achievement rates in both the 
Very-Elderly and Young/Elderly patients (p<0.05 and p<0.001, respectively). However, 
there was no significant difference noted for the target achievement rates between the 
Very-Elderly and Young/Elderly patients. 
Effects on morning SBP reduction 
Changes in the morning SBP (morning SBP) during the 3-month treatment were 
investigated on the basis of the available-case analysis, i.e., an analysis that examined 
subjects with available data for both the morning SBP measurements before and after 
the 3-month treatment. The morning SBP values were -20.2±14.8 mmHg for the 
combination therapy and -7.1±12.7 mmHg for the high-dose therapy in the Very-Elderly 
patients (Figure 2). The morning SBP values in the Young/Elderly patients were 
-18.1±11.7 mmHg for the combination therapy and -9.1±12.4 mmHg for the high-dose 
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therapy. Combination therapy induced a greater SBP reduction compared to the 
high-dose therapy in both age groups (p<0.01 for both). However, there was a similar 
efficacy of the two therapies for the morning SBP reduction between the Young/Elderly 
and Very-Elderly patients. 
Effects on eGFR and serum K levels 
Baseline eGFR was lower in the Very-Elderly patients versus the Young/Elderly patients 
of either therapy group, whereas the serum K levels were similar among the 4 groups at 
baseline (Table 1). The intention-to-treat analysis showed that neither treatment caused 
any significant changes in the eGFR and serum K levels in either of the age groups 
(Figure 3). 
Effects on evening and office SBP 
Baseline values for the evening and office SBP did not differ among the Very-Elderly 
combination, Very-Elderly high-dose, Young/Elderly combination, and Young/Elderly 
high-dose groups (Table 1). Both the combination and high-dose therapies significantly 
reduced the evening and office SBP in the Very-Elderly and Young/Elderly patients 
(p<0.01 for all) (Figure 4A). The combination therapy induced a greater office SBP 
reduction versus the high-dose therapy in the Very-Elderly and Young/Elderly patients 
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(p<0.01 and p<0.05, respectively) (Figure 4B). A similar trend was observed for the 
effects on the evening SBP, although the changes did not reach statistical significance. 
There was no difference observed for the combination or high-dose therapy with regard 
to the extent of the induced reduction in the evening and office SBP between the 
Very-Elderly and Young/Elderly patients. 
 
Discussion 
The present study demonstrated that the losartan/HCTZ combination therapy was 
superior to the high-dose losartan therapy in controlling morning hypertension in the 
Very-Elderly patients (Figure 1). In addition, the combination therapy reduced morning 
SBP in the Very-Elderly patients to levels that were similar to those of the 
Young/Elderly patients (Figure 2). Moreover, both the combination and high-dose 
therapies were found to be safe and tolerable for the Very-Elderly as well as the 
Young/Elderly patients (Table 2).  
Morning hypertension, which is a characteristic feature of elderly 
hypertension, is associated with an increased cerebrovascular and cardiovascular event 
risk (9-11). Since low-renin essential hypertension and hypertension with increased 
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salt-sensitivity are often found in elderly patients (12), salt and water retention are 
believed to be involved in the mechanism of morning hypertension in this patient group. 
Thus, it has been suggested that HCTZ would be effective in the treatment of morning 
hypertension in the elderly. In addition, since HCTZ has a very long duration of action 
and a large trough/peak ratio, it is also considered to be suitable for stably lowering the 
BP over a 24-hour period. The current guidelines for the management of hypertension in 
Europe, the United States and Japan recommend the use of a low dose of thiazide 
diuretics as one of the first-line drugs for the treatment of elderly hypertension (13-15). 
As we found that more than 90% of the Very-Elderly patients in the present study had 
received an ARB at baseline (Table 1), this suggests that the addition of HCTZ or an 
increased dose of ARB might be a practical option as the next step in controlling 
morning hypertension. However, due to concern for potential adverse effects, e.g., 
dehydration, electrolyte abnormality, and excess BP lowering, diuretics are underused in 
the treatment of elderly hypertension in Japan. Although our previous MAPPY study 
demonstrated that the losartan/HCTZ combination was both safe and superior to 
high-dose losartan in treating morning hypertension (6), this study did not determine if 
these results were also applicable to the very elderly patient population. 
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 In the present study, our safety assessment indicated that both the 3-month 
losartan/HCTZ combination and the high-dose losartan therapies were safe and 
tolerable in the Very-Elderly as well as the Young/Elderly patients. Also, it was 
noteworthy that the combination therapy did not induce any serious adverse effects or 
affect the renal function and serum K in the Very-Elderly patients. 
 The most important finding of the present study was that the losartan/HCTZ 
combination therapy induced a greater reduction in the morning SBP and a higher target 
achievement rate of the morning BP, as compared with the high-dose losartan therapy in 
the Very-Elderly patients (Figures 1 and 2). In addition, the beneficial effects found for 
the Very-Elderly patients were comparable to those observed in the Young/Elderly 
patients. These observations are in line with the Hypertension in the Very-Elderly Trial 
(HYVET), which demonstrated that indapamide-based therapy effectively reduced 
all-cause mortality and cardiovascular events in hypertensive patients who were ≥80 
years (16). 
 Although our results suggested that one of the beneficial effects of the 
losartan/HCTZ combination therapy was control of the evening and office SBP, these 
changes were less consistent than those found for the morning SBP, especially in the 
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Very-Elderly patients (Figure 4). The reason for the differences observed remains 
unknown at the present. However, these observations might be related to the fact that 
older subjects are known to have larger fluctuations of their office BP (i.e., visit-to-visit 
BP variability) (17) and that the evening SBP is strongly influenced by the measurement 
conditions, such as drinking alcohol and bathing (18). 
In the present study, most subjects received an ARB or ACEI before being 
switched to the losartan/HCTZ combination or high-dose losartan (Table 1). While it 
would have been interesting to be able to determine the possible difference in the effects 
on the safety and efficacy of the test drugs between the preceding ARB and ACEI, the 
small number of patients receiving ACEI precluded any further analysis of this in our 
study. It has also been shown that the administration of an -blocker prior to going to 
bed is useful in the management of morning hypertension (19). Thus, co-administration 
with an -blocker might have an impact on the efficacy of the losartan/HCTZ 
combination and the high-dose losartan. However, the number of patients taking an 
-blocker in our study was too small for a statistical evaluation. Moreover, there were 
no data available on whether an -blocker was prescribed in the morning or in the 
evening in these patient groups. Therefore, the potential differential effects between 
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ARB and ACEI and potential effects of -blockers will need to be further investigated 
in future studies. 
 There were several limitations for the current study. First, there were only a 
small number of patients in each group, as this was a subanalysis of our previous 
MAPPY study. Therefore, we need to be careful in interpreting the results of the present 
study due to the low statistical power of the analysis. Second, high-dose losartan was 
only administered once every morning in the current study. It is possible that the 
administration of high-dose losartan would be more effective for controlling morning 
hypertension if it was administered once in the evening or if the dose was halved and 
then administered both in the morning and in the evening. This issue will need to be 
addressed in a future study. Third, the majority of the patients enrolled in this study 
were not observed during the summer season. Thus, we cannot deny the possibility that 
there would be an increased prevalence of adverse effects for the combination therapy 
during the summer, such as dehydration, fainting, symptomatic hypotension, and renal 
dysfunction. Finally, a further randomized study with a larger patient number and longer 
observation period will need to be undertaken in order to determine the long-term safety 
and efficacy of the losartan/HCTZ combination therapy for cardiovascular morbidity 
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and mortality in very elderly patients. 
In conclusion, losartan/HCTZ combination therapy was safe and effective in 
controlling morning hypertension in very elderly patients with ages >75 years, as well 
as in young/elderly patients who were <75 years. In addition, losartan/HCTZ 
combination therapy was superior to high-dose losartan therapy in lowering the morning 
SBP in very elderly patients. These findings suggest that the addition of HCTZ may be a 
desirable option even in very elderly patients when the target morning BP cannot be 
achieved by only an ARB. 
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Figure legends 
Figure 1. Effects of a 3-month treatment with 50 mg losartan/12.5 mg 
hydrochlorothiazide combination therapy (Combination) or high-dose (100 mg) losartan 
therapy (High-dose) on the systolic blood pressure (BP). The intention-to-treat analysis 
was performed for the combination therapy (n=69) and high-dose therapy (n=66) 
groups in the Young/Elderly (<75 years) and for the combination therapy (n=32) and 
high-dose therapy (n=34) in the Very-Elderly patients (>75 years). Bar=1 x SD. 
**p<0.01 vs. Baseline. #p<0.05 and ##p<0.01 vs. High-dose. 
 
Figure 2. Effects of a 3-month treatment with losartan/hydrochlorothiazide combination 
therapy (Combination) and high-dose losartan therapy (High-dose) on the changes in 
the morning SBP (morning SBP). The morning SBP change was calculated on the 
basis of the available-case analysis in the subjects who had paired data available for 
both the morning SBP values at baseline and post-treatment (Young/Elderly 
combination, n=53; Young/Elderly high-dose, n=47; Very-Elderly combination, n=21; 
Very-Elderly high dose, n= 24). NS, not significant. 
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Figure 3. Effects of 3-month treatment with losartan/hydrochlorothiazide combination 
therapy (Combination) and high-dose losartan therapy (High-dose) on estimated 
glomerular rate (eGFR) (A) and serum potassium (K) (B). The intention-to-treat 
analysis was performed as described in Figure 1. *p<0.05 vs. Baseline. #p<0.05 vs. 
High-dose. 
 
Figure 4. Effects of 3-month losartan/hydrochlorothiazide combination therapy 
(Combination) and high-dose losartan therapy (High-dose) on the evening and office 
SBP levels (A, the intention-to-treat analysis) and on the evening and office SBP 
changes (evening SBP and office SBP) (B, the available-case analysis). Bar=1 x SD. 
**p<0.01 vs. Baseline. ##p<0.01 vs. High-dose. 
Table 1. Baseline characteristics and demographic 
 
Young/elderly Very elderly 
  Patients <75 years old Patients >75 years old   
  Combination High dose Combination High dose P-value 
Number, n 69 66 32 34 - 
Age, year 62.6 ± 9.0 62.7 ± 8.7 79.1 ± 4.1 78.2 ± 3.1 0.000 
Male, n (%) 42(58.8) 29(42.9) 19(62.1) 12(34.4) 0.039 
BMI, kgm-2 24.0 ± 3.0 24.6 ± 3.1 23.9± 3.1 22.6 ± 3.1 0.068 
Morning BP 
 Systolic BP, mmHg 148.9 ± 9.2 150.9 ± 10.0 153.8 ± 11.2 153.3 ± 10.4 0.142 
 Diastolic BP, mmHg 85.7 ± 9.6 86.9 ± 9.4 80.6 ± 5.5 79.3 ± 7.3 0.001 
Evening BP 
 Systolic BP, mmHg 140.3 ± 12.1 139.8 ± 10.4 145.0 ± 15.9 140.1 ± 12.0 0.497 
 Diastolic BP, mmHg 78.9 ± 10.0 77.4 ± 8.1 73.6 ± 7.6 73.4 ± 8.9 0.052 
Office BP 
 Systolic BP, mmHg 146.1± 13.2 148.7 ± 13.6 150.1 ± 17.0 146.5 ± 15.3 0.622 
 Diastolic BP, mmHg 82.5 ± 11.8 81.6± 10.4 75.7 ± 7.8 75.9 ± 9.3 0.006 
eGFR, ml per min per 1.73m2 70.3 ± 12.5 76.0 ± 16.6 60.8 ± 14.6 62.1 ± 15.1 0.000 
K, mmoll-1 4.3 ± 0.3 4.3 ± 0.4 4.4 ± 0.4 4.3 ± 0.4 0.322 
Uric acid, mg dl-1 5.6 ± 1.4 5.7 ± 1.5 6.1 ± 2.2 5.7 ± 1.4 0.608 
LDL cholesterol, mg dl-1 108.8 ± 30.8 120.8 ± 28.6 103.6 ± 28.5 111.6 ± 22.8 0.069 
HDL cholesterol, mg dl-1 59.6 ± 14.4 57.0 ± 14.6 56.1 ± 12.9 58.1 ± 15.9 0.724 
Triglycerides, mg dl-1a 110 [55-290] 123 [37-270] 93 [44-241] 94 [41-166] 0.030 
HbA1c, % 5.6 ± 0.6 5.5 ± 0.4 5.9 ± 0.6 5.5 ± 0.6 0.163 
BNP, pg ml-1a 
22.1 
[4.0-229.4] 
28.1 
[2.1-188.0] 
42.6 
[5.9-284.0] 
60.7 
[16.6-222.2] 
0.002 
Comorbidity n (%) 
Diabetes 11(16.4) 7(11.1) 9(31.0) 6(18.9) 0.134 
Dyslipidemia 25(37.3) 27(42.9) 12(41.4) 14(43.8) 0.906 
CAD 5(7.5) 4(3.2) 5(17.2) 5(12.5) 0.501 
CVD 3(5.8) 2(4.3) 5(17.2) 4(12.5) 0.235 
Smoking 5(8.1) 11(19.0) 3(10.3) 4(12.5) 0.339 
Treatment during the run-in period 
No. of antihypertensive drug 1.63 ± 0.93 1.41 ± 0.62 1.95 ± 0.74 1.79 ± 0.78 
ACEi  1(1.6) 4(6.6) 1(3.6) 1(3.2) 0.879 
ARB 56(88.9) 53(86.9) 26(92.9) 29(90.6) 0.936 
Ca channel blockers 24(37.5) 24(39.3) 13(46.4) 20(62.5) 0.087 
α-blockers 6(9.4) 0(0.0) 2(7.1) 1(3.1) 0.092 
β-blockers 15(23.4) 5(8.2) 7(25.0) 5(15.6) 0.092 
Loop diuretics 0(0.0) 1(1.6) 1(3.6) 1(3.1) 0.524 
Spironolactone 1(1.6) 1(1.6) 1(3.6) 0(0.0) 0.758 
 
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; LDL, low-density 
lipoprotein; HDL, low-density lipoprotein; BNP, brain-type natriuretic peptide; CAD, coronary artery 
disease; CVD, cerebrovascular disease; ARB, angiotensin receptor blocker; ACEi, angiotensin-converting 
enzyme inhibitor. 
Data are described as n (%), mean±SD, or geographic mean (95% confidence interval). 
 
Table 2. Medication Adherence and Adverse Events 
Medication adherence, % 1 month 2 month 3 month 
Young/Elderly ( <75 ) 
Combination 
>80 % 98  100  97  
50-80 % 2  0  2  
<50 % 0  0  2  
High -dose (%) 
>80 % 98  98  100  
50-80 % 2  2  0  
<50 % 0  0  0  
  
Very-Elderly ( >75 ) 
Combination (%) 
>80 % 100  100  100  
50-80 % 0  0  0  
<50 % 0  0  0  
High -dose (%) 
>80 % 96  96  97  
50-80 % 4  2  3  
<50 %  0  0    0  
 
 
Adverse events, n (%)  N 
Intractable 
high BP 
Headache Hot flash itchy eye Urticaria Palpitation
Creatinine 
elevation 
Total 
Young/Elderly ( <75 ) 
Combination 69 1 (1.4) 0 0 0 0 0 0 1 (1.4) 
High -dose 66 1 (1.5) 1 (1.5) 0 0 1 (1.5) 0 0 3 (4.5) 
Very-Elderly ( >75 ) 
Combination 32 0 1 (3.1) 0 1(3.1) 0 0 1 (3.1) 3 (9.4) 
High -dose 34 0 0 1 (2.9) 0 0 1 (2.9) 0 2 (5.9) 
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